{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:24:00Z","timestamp":1792682640460,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T00:00:00Z","timestamp":1729987200000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31-DA-049613"],"award-info":[{"award-number":["F31-DA-049613"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23-DA-041294"],"award-info":[{"award-number":["K23-DA-041294"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24-AI-118591"],"award-info":[{"award-number":["K24-AI-118591"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-AI-094189"],"award-info":[{"award-number":["P30-AI-094189"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DA-048063"],"award-info":[{"award-number":["R01-DA-048063"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AI-102623"],"award-info":[{"award-number":["T32-AI-102623"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-DA-007292"],"award-info":[{"award-number":["T32-DA-007292"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-DA-036297"],"award-info":[{"award-number":["U01-DA-036297"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.drugalcdep.2023.111007","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T02:36:35Z","timestamp":1697855795000},"page":"111007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals"],"prefix":"10.1016","volume":"253","author":[{"given":"Catelyn R.","family":"Coyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Gicquelais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky L.","family":"Genberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2722-0922","authenticated-orcid":false,"given":"Jacquie","family":"Astemborski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseun","family":"Falade-Nwulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti H.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2023.111007_bib1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.12370","article-title":"Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents","volume":"34","author":"Alavi","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108526","article-title":"Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: a qualitative study","volume":"220","author":"Assoumou","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib5","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/liv.14227","article-title":"The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: impact of direct acting antivirals","volume":"39","author":"Bartlett","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10810730.2017.1414902","article-title":"Mapping the barriers and facilitators of HCV treatment initiation in methadone maintenance therapy patients: implications for intervention development","volume":"23","author":"Bass","year":"2018","journal-title":"J. Health Commun."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5694\/j.1326-5377.1990.tb136900.x","article-title":"Hepatitis C virus in intravenous drug users","volume":"153","author":"Bell","year":"1990","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/ije\/25.1.204","article-title":"Prevalence of antibiotics to hepatitis C in a population of intravenous drug users in Valencia, Spain, 1990-1992","volume":"25","author":"Bolumar","year":"1996","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib10","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib11","doi-asserted-by":"crossref","first-page":"e2194","DOI":"10.1093\/cid\/ciaa1124","article-title":"A treatment-as-prevention trial to eliminate hepatitis C among men who have sex with men living with human immunodeficiency virus (HIV) in the Swiss HIV Cohort Study","volume":"73","author":"Braun","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jsat.2017.01.017","article-title":"Examination of the hepatitis C virus care continuum among individuals with an opioid use disorder in substance use treatment","volume":"76","author":"Brown","year":"2017","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib13","series-title":"Eliminating the Public Health Problem of Hepatitis B and C in the United States","author":"Buckley","year":"2016"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M15-0320","article-title":"Limited access to new hepatitis C virus treatment under state medicaid programs","volume":"163","author":"Canary","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.7326\/M21-3846","article-title":"Impact of hepatitis C treatment uptake on cirrhosis and mortality in persons who inject drugs: a longitudinal, community-based cohort study","volume":"175","author":"Cepeda","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/apt.15291","article-title":"The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States","volume":"50","author":"Chhatwal","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/liv.12536","article-title":"Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice","volume":"35","author":"Crespo","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib18","unstructured":"Division of Viral Hepatitis at CDC, 2020. Viral Hepatitis Surveillance \u2014 United States, 2020."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib19","unstructured":"Division of Viral Hepatitis at CDC, 2017. Viral Hepatitis Surveillance \u2014 United States, 2017."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib20","unstructured":"Division of Viral Hepatitis at CDC, 2011. Viral Hepatitis Surveillance \u2014 United States, 2011."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1000","article-title":"Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial","volume":"163","author":"Everson","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","article-title":"Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore","volume":"100","author":"Falade-Nwulia","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","article-title":"Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe","volume":"68","author":"Fraser","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.14309\/ajg.0000000000002041","article-title":"Results of a model of delivering hepatitis C care in a homeless metropolitan population in England","volume":"118","author":"Guerra-Veloz","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7517-10-7","article-title":"Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors","volume":"10","author":"Harris","year":"2013","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib27","doi-asserted-by":"crossref","first-page":"E955","DOI":"10.1093\/cid\/ciac175","article-title":"Sustained impact of the coronavirus disease 2019 pandemic on hepatitis C virus treatment initiations in the United States","volume":"75","author":"Hoenigl","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib28","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugpo.2017.05.022","article-title":"Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia","volume":"47","author":"Iversen","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011","volume":"21","author":"Iversen","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-023-00831-9","article-title":"Treated like a Human Being\u201d: perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City","volume":"20","author":"Kapadia","year":"2023","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib33","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/597350","article-title":"Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection","volume":"48","author":"Kirk","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.amepre.2022.04.024","article-title":"Dispensing of HIV and Hepatitis C antivirals during COVID-19: an interrupted time-series analysis of U.S. National Data","volume":"63","author":"Levengood","year":"2022","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/apt.14328","article-title":"Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents","volume":"46","author":"Lin","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.gtc.2015.07.003","article-title":"Natural history of hepatitis C","volume":"44","author":"Lingala","year":"2015","journal-title":"Gastroenterol. Clin. N.\u00a0Am."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/M16-2350","article-title":"Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014","volume":"166","author":"Ly","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/0033354918772059","article-title":"Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population","volume":"133","author":"Marcus","year":"2018","journal-title":"Public Health Rep."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3851\/IMP2085","article-title":"Stability of liver fibrosis among HCV-infected injection drug users","volume":"17","author":"Mehta","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"Mehta","year":"2007","journal-title":"J. Community Health"},{"issue":"Suppl 3","key":"10.1016\/j.drugalcdep.2023.111007_bib42","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/01.aids.0000192088.72055.90","article-title":"A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV\/HCV-co-infected injection drug users","volume":"19","author":"Mehta","year":"2005","journal-title":"Aids"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249585","article-title":"Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco","volume":"16","author":"Mirzazadeh","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib44","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1525-1497.2005.0161.x","article-title":"Barriers to the treatment of hepatitis C. Patient, provider, and system factors","volume":"20","author":"Morrill","year":"2005","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib45","doi-asserted-by":"crossref","unstructured":"National Academies of Sciences, Engineering, and Medicine, 2020. Opportunities to Improve Opioid Use Disorder and Infectious Disease Services. National Academies Press, Washington, D.C. https:\/\/doi.org\/10.17226\/25626.","DOI":"10.17226\/25626"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib46","unstructured":"National Viral Hepatitis Roundtable (NVHR), Center for Health Law and Policy Innovation of Harvard Law School (CHLPI),\u00a02020. Hepatitis C: State of Medicaid Access."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib47","unstructured":"National Viral Hepatitis Roundtable (NVHR), Center for Health Law and Policy Innovation of Harvard Law School (CHLPI),\u00a02017. Hepatitis C: State of Medicaid Access."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2017.01.015","article-title":"Retention in buprenorphine treatment is associated with improved HCV care outcomes","volume":"75","author":"Norton","year":"2017","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib49","doi-asserted-by":"crossref","first-page":"516","DOI":"10.6061\/clinics\/2017(09)01","article-title":"Accuracy of transient elastography-FibroScan(R), acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C","volume":"72","author":"Ragazzo","year":"2017","journal-title":"Clinics"},{"key":"10.1016\/j.drugalcdep.2023.111007_bib50","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10620-017-4608-9","article-title":"Primary care and hepatology provider-perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence","volume":"62","author":"Rogal","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1665-2681(19)30786-0","article-title":"Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics","volume":"14","author":"Schaeffer","year":"2015","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib52","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/MCG.0000000000000857","article-title":"Uptake of and factors associated with direct-acting antiviral therapy among patients in the chronic hepatitis cohort study, 2014 to 2015","volume":"52","author":"Spradling","year":"2018","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.06.002","article-title":"The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone","volume":"29","author":"Sylvestre","year":"2005","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/s40900-023-00474-x","article-title":"Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment","volume":"9","author":"Talal","year":"2023","journal-title":"Res. Involv. Engagem."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00146260","article-title":"A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam","volume":"9","author":"van Ameijden","year":"1993","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib56","first-page":"75","article-title":"The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants","volume":"109","author":"Vlahov","year":"1991","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib57","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1093\/infdis\/jiaa142","article-title":"Psychosocial factors and the care cascade for hepatitis C treatment colocated at a syringe service program","volume":"222","author":"Winetsky","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41395-018-0033-8","article-title":"Race\/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment","volume":"113","author":"Wong","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib59","unstructured":"World Health Organization, 2016. Combating Hepatitis B and C to Reach Elimination by 2030. World Health Organization.\u00a0http:\/\/www.who.int\/iris\/handle\/10665\/206453."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/08897077.2018.1485128","article-title":"Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada","volume":"39","author":"Young","year":"2018","journal-title":"Subst. Abus."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib61","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib62","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s10620-019-05877-z","article-title":"Provider perceptions of hepatitis C treatment adherence and initiation","volume":"65","author":"Zhang","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.drugalcdep.2023.111007_bib63","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.2105\/AJPH.2014.302142","article-title":"Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics","volume":"104","author":"Zibbell","year":"2014","journal-title":"Am. J. Public Health"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871623012450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871623012450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:29:17Z","timestamp":1759829357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871623012450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":63,"alternative-id":["S0376871623012450"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.111007","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.111007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111007"}}